
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Conference

Your unrestricted view into eyecare conferences across the spectrum. Gain exclusive access to Modern Retina® expert-led conference coverage from major meetings throughout the year featuring articles, videos, and insights shared by prominent experts of the retinal and ophthalmic communities.

News

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

AAO 2020: Alimera highlights NEW DAY Study for sustained-release intravitreal implant